AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress
Go back to AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress| AbbVie (NYSE: ABBV) | Delayed: 263.96 -0.06 (0.02%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $264.02 | 52 Week High | $68.12 | |||
| Open | $263.29 | 52 Week Low | $50.71 | |||
| Day High | $266.34 | P/E | 57.26 | |||
| Day Low | $262.44 | EPS | $4.61 | |||
| Volume | 8,162,114 | |||||
| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 146.23 -5.6 (3.69%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $151.83 | 52 Week High | $58.46 | |||
| Open | $152.63 | 52 Week Low | $31.25 | |||
| Day High | $152.63 | P/E | N/A | |||
| Day Low | $146.06 | EPS | $-0.69 | |||
| Volume | 2,815,385 | |||||
